centchroman has been researched along with 3,3'-diindolylmethane in 2 studies
| Studies (centchroman) | Trials (centchroman) | Recent Studies (post-2010) (centchroman) | Studies (3,3'-diindolylmethane) | Trials (3,3'-diindolylmethane) | Recent Studies (post-2010) (3,3'-diindolylmethane) |
|---|---|---|---|---|---|
| 157 | 12 | 47 | 409 | 16 | 252 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meeran, SM; Mondal, P; Natesh, J; Penta, D | 2 |
2 other study(ies) available for centchroman and 3,3'-diindolylmethane
| Article | Year |
|---|---|
Dietary bioactive diindolylmethane enhances the therapeutic efficacy of centchroman in breast cancer cells by regulating ABCB1/P-gp efflux transporter.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Biological Transport; Cell Line, Tumor; Centchroman; Estrogen Antagonists; Gene Expression Regulation; Humans; Indoles; Multidrug Resistance-Associated Proteins; Paclitaxel; Protein Binding; Verapamil | 2021 |
Dietary Diindolylmethane Enhances the Therapeutic Effect of Centchroman in Breast Cancer by Inhibiting Neoangiogenesis.
Topics: Cell Line, Tumor; Cell Proliferation; Centchroman; Humans; Neovascularization, Pathologic; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2023 |